Posted from: Thursday, January 05, 2017 - 05:26 PM - Present

Basaglar Now Available

December 15, 2016 - Lilly and Boehringer Ingelheim’s Basaglar® (insulin glargine), the first follow-on to Sanofi’s Lantus® (insulin glargine) was launched in the U.S. It is a long-acting insulin indicated to improve glycemic control for adult and pediatric patients with type 1 diabetes, and for adults with type 2 diabetes. It is supplied in cartons of five KwikPen® devices that each contain 3mL of U-100 (100 units per mL) of Basaglar. Recommended dosing is individualized according to the patient’s blood glucose levels. Basaglar is given as one subcutaneous injection daily at about the same time of day.

Basaglar is not a biosimilar or generic to Lantus. It is a brand product and will compete with the other brand long-acting insulins for market share. These products include Lantus, Levemir® (insulin detemir – Novo Nordisk), Tresiba® (insulin degludec – Novo Nordisk) and Toujeo® (insulin glargine – Sanofi). Merck/Samsung Bioepis has a follow-on insulin glargine (MK-1293) currently under FDA review for which approval is anticipated during the 2nd Quarter of 2017. Additional competition within the long-acting insulin market should help alleviate some of the price increases common to this category.


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan


Last Updated Friday, November 15, 2019 - 10:40 AM.